Nicolas Lindegger Email & Phone Number

After a PhD in cardiac physiology, ion channel electrophysiology, pharmacology, and spectroscopy in the laboratory of Ernst Niggli in Bern, I studied the role of Na+ and RyR2a channels in the generation of cardiac arrhythmias at Columbia University. After 9.5 years of preclinical research, I started my carreer in the pharmaceutical industry, first as clinical pharmacologist at Actelion, then as clinical trial leader at Novartis. In both positions I developed, managed, and reported phase I and proof-of-concept clinical studies. I then transitioned to Roche's Global Medical Affairs, as International Scientific Director in the HER2 positive breast cancer team. This was the start of a new passion, where the work we do daily directly impacts the lives of patients - and friends - and their families all over the world. In the last 5 years, I took the medical lead for Herceptin, worked on Perjeta, Kadcyla, and shaped the clinical development plan for TECENTRIQ in HER2+ breast cancer. I also developed a keen interest in epidemiology (ie., the only way to study sequencing and effectiveness) as well as on the treatment approaches to brain metastases. I am now medical director at Seattle Genetics, responsible for breast cancer and especially for Tucatinib in Europe.Specialties: Clinical: writing clinical protocols and clinical study reports, selection and management of CROs, HA / EC submissions, management of outsourced clinical trials, and PK and PD analysis, medical education, external experts and collaborative group management, adboards, oversight of commercial activities, access and pricing discussions, epidemiology, publication strategy, launch strategy, etc.

Listed skills include Clinical Trials, Clinical Development, Clinical Research, Pharmacology, and 18 others.